We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

763 hedge funds and large institutions have $9.17B invested in State Street SPDR S&P Biotech ETF in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 255 increasing their positions, 255 reducing their positions, and 99 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 255 | Existing positions reduced: 255

3% less funds holding

Funds holding: 783 → 763 (-20)

4.61% less ownership

Funds ownership: 126.63% → 122.01% (-4.6%)

11% less first-time investments, than exits

New positions opened: 88 | Existing positions closed: 99

20% less capital inflows, than outflows

Capital inflows: $1.34B | Capital outflows: $1.69B

22% less funds holding in top 10

Funds holding in top 10: 23 → 18 (-5)

46% less call options, than puts

Call options by funds: $1.6B | Put options by funds: $2.95B

Holders
763
Holders Change
-20
Holders Change %
-2.55%
% of All Funds
10.98%
Holding in Top 10
18
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-21.74%
% of All Funds
0.26%
New
88
Increased
255
Reduced
255
Closed
99
Calls
$1.6​B
Puts
$2.95​B
Net Calls
-⁠$1.35​B
Net Calls Change
+$368​M

XBI Hedge Fund Activity: Q2 2024 in Review

763 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2024, worth a combined $9.17B — down 5.9% from $9.8B a quarter earlier.

Sellers outnumbered buyers: 99 funds closed out of XBI and 88 opened new positions — a net loss of 11 holders — while 255 trimmed existing stakes and 255 added.

The largest buyer was JP Morgan Chase, adding an estimated $402M. The largest seller was Citadel Advisors, cutting an estimated $167M.

  • 763 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2024, down from 783 in Q1 2024.
  • Funds reported $9.17B of State Street SPDR S&P Biotech ETF stock for Q2 2024, down 5.9% quarter-over-quarter.
  • 88 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2024 and 99 closed out, a net change of -11 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q2 2024 was JP Morgan Chase, an estimated $402M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q2 2024 was Citadel Advisors, an estimated $167M sold.

Based on aggregated 13F filings for Q2 2024.